136 In the index

Bremelanotide PT-141

An FDA-approved medication (Vyleesi) for low sexual desire in women, also studied off-label for erectile dysfunction. Human trials back up modest improvements in sexual desire, though nausea and a temporary rise in blood pressure are common side effects.

Also known as PT-141, Vyleesi, Bremelanotida, 6Y24O4F92S, PT 141, Bremelanotidum, RefChem:58355, Bremelanotide [USAN:INN], Vyleesi (TN)

Effects Libido

Routes Nasal Subcutaneous

Legal status Prescription drug

WADA Not listed

Molecular Structure of C₅₀H₆₈N₁₄O₁₀

Drag to rotate · scroll to zoom

PubChem has no 3D conformer for this molecule, so this is the flat structure.

Chemistry

Formula: C50H68N14O10
Molar mass: 1025.2
CAS: 189691-06-3
PubChem CID: 9941379
IUPAC name: (3S,6S,9R,12S,15S,23S)-15-[[(2S)-2-acetamidohexanoyl]amino]-9-benzyl-6-[3-(diaminomethylideneamino)propyl]-12-(1H-imidazol-5-ylmethyl)-3-(1H-indol-3-ylmethyl)-2,5,8,11,14,17-hexaoxo-1,4,7,10,13,18-hexazacyclotricosane-23-carboxylic acid
InChIKey: FFHBJDQSGDNCIV-MFVUMRCOSA-N

Reported dosing

Approved label

What has been reported in the literature and by users. This is a record of what is done, not a recommendation.

Typical dose 1.75 mg

Reported range 1.75 mg per dose, as needed

Route Subcutaneous injection (auto-injector)

Frequency As needed, at least 45 minutes before anticipated activity; no more than once in 24 hours or 8 times per month

Duration As needed

FDA-approved prescription medication (Vyleesi) for hypoactive sexual desire disorder in women; also studied historically (as PT-141) for male erectile dysfunction, an off-label use.

Where this comes from FDA prescribing information

These figures are recorded for reference and are not a recommendation. Dosing is a decision for you and a clinician.